Literature DB >> 27774138

Discovery of Fluorescence Polarization Probe for the ELISA-Based Antagonist Screening of α1-Adrenergic Receptors.

Zhao Ma1, Zhenzhen Liu1, Tianyu Jiang1, Tianchao Zhang1, Huateng Zhang1, Lupei Du1, Minyong Li1.   

Abstract

High-throughput screening (HTS) of ligand library to find new active molecules for G protein-coupled receptors is still a major interest, as well as an actual challenge. Fluorescence polarization (FP) assay portrays an essential role in HTS; however, in many cases, it was restricted by the absence of FP probes, the narrow measurement window, and low signal-to-noise (S/N) ratio. Herein, based on the modification of our previous probe 1 (QFL), we discovered an FP probe 3 (QGGFL) for α1-adrenergic receptors (α1-ARs), which has satisfactory fluorescence intensity, specific binding ability to receptors, and suitable fluorescence properties that were compatible with the filters in the FP system. Meanwhile, an "ELISA-like" strategy was designed for FP-based HTS assay in which proteins were adhered into a solid phase to improve the measurement window and S/N ratio. With fluorescent antagonist QGGFL and the ELISA strategy, we succeeded in establishing the first competitive binding FP assay for α1-AR antagonists as the alternative of the radioligand binding assay.

Keywords:  ELISA; GPCR; fluorescence polarization; fluorescent probe; ligand screening; α1-Adrenergic receptors

Year:  2016        PMID: 27774138      PMCID: PMC5066147          DOI: 10.1021/acsmedchemlett.6b00048

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  27 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

2.  High throughput fluorescence polarization: a homogeneous alternative to radioligand binding for cell surface receptors.

Authors:  M Allen; J Reeves; G Mellor
Journal:  J Biomol Screen       Date:  2000-04

Review 3.  Fluorescence polarization and anisotropy in high throughput screening: perspectives and primer.

Authors:  J C Owicki
Journal:  J Biomol Screen       Date:  2000-10

4.  Fluorescence polarization assays for high throughput screening of G protein-coupled receptors.

Authors:  P Banks; M Gosselin; L Prystay
Journal:  J Biomol Screen       Date:  2000-06

Review 5.  Alpha1-adrenergic receptors: new insights and directions.

Authors:  M T Piascik; D M Perez
Journal:  J Pharmacol Exp Ther       Date:  2001-08       Impact factor: 4.030

Review 6.  Fluorescence polarization immunoassays and related methods for simple, high-throughput screening of small molecules.

Authors:  David S Smith; Sergei A Eremin
Journal:  Anal Bioanal Chem       Date:  2008-02-10       Impact factor: 4.142

7.  Quantitative imaging in live human cells reveals intracellular alpha(1)-adrenoceptor ligand-binding sites.

Authors:  J F Mackenzie; C J Daly; J D Pediani; J C McGrath
Journal:  J Pharmacol Exp Ther       Date:  2000-08       Impact factor: 4.030

8.  Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.

Authors:  N Kyprianou; C M Benning
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

9.  Differences in the cellular localization and agonist-mediated internalization properties of the alpha(1)-adrenoceptor subtypes.

Authors:  Dan Chalothorn; Dan F McCune; Stephanie E Edelmann; Mary L García-Cazarín; Gozoh Tsujimoto; Michael T Piascik
Journal:  Mol Pharmacol       Date:  2002-05       Impact factor: 4.436

10.  Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction.

Authors:  J V Partin; I E Anglin; N Kyprianou
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

View more
  1 in total

Review 1.  Epigenetic assays for chemical biology and drug discovery.

Authors:  Sheraz Gul
Journal:  Clin Epigenetics       Date:  2017-04-21       Impact factor: 6.551

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.